Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01804101 · ClinicalTrials.gov registry record · NA
Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia
A NA study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 48
- Enrollment target
NCT01804101 is a NA study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 48 participants.
The verdict
NCT01804101, a NA study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
Study Summary
This randomized clinical trial studies liposomal cytarabine-daunorubicin CPX-351 in treating patients with untreated myelodysplastic syndrome or acute myeloid leukemia. Drugs used in chemotherapy, such as liposomal cytarabine-daunorubicin CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Liposomal Cytarabine-Daunorubicin CPX-351
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2013-05-07 |
| Est. Completion | 2017-01-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01804101
The ClinicalTrials.gov registry entry for NCT01804101 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01804101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01804101 about?
NCT01804101 is a clinical study titled "Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia". This randomized clinical trial studies liposomal cytarabine-daunorubicin CPX-351 in treating patients with untreated myelodysplastic syndrome or acute myeloid leukemia. Drugs used in chemotherapy, such as liposomal cytarabine-daunorubicin CPX-351, work in different ways to stop the growth of cancer ...
What is the current status of trial NCT01804101?
This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2013-05-07. Estimated completion is 2017-01-10.
What interventions are being tested in trial NCT01804101?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Liposomal Cytarabine-Daunorubicin CPX-351 (DRUG).
Who is sponsoring clinical trial NCT01804101?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.